McNair et al.44. McNair DM, Frankenthaler LM, Czerlinsky T, White TW, Sasson S, Fisher S. Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berl). 1982;77:7-10.
|
Diazepam |
31 (31/0) |
(18-30) |
No |
Guimaraes et al.2222. Guimarães FS, Zuardi AW, Graeff FG. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J Psychopharmacol. 1987;1:184-92.
|
Chlorimipramine, maprotilime, lorazepam |
10 (4/6) |
(19-34) |
No |
Zuardi et al.1313. Westenberg PM, Bokhorst CL, Miers AC, Sumter SR, Kallen VL, van Pelt J, et al. A prepared speech in front of a pre-recorded audience: subjective, physiological, and neuroendocrine responses to the Leiden Public Speaking Task. Biol Psychol. 2009;82:116-24.
|
Cannabidiol, ipsapirone, diazepam |
10 (5/5) |
(20-30) |
VAMS-Anxiety, SBP |
Kapczinski et al.2323. Kapczinski F, Curran HV, Gray J, Lader M. Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology (Berl). 1994;114:187-9.
|
Flumazenil |
10 (5/5) |
(18-43) |
No |
Palma et al.66. Palma SM, Guimarães FS, Zuardi AW. Anxiety induced by simulated public speaking and stroop color word test in healthy subjects: effects of different trait-anxiety levels. Braz J Med Biol Res. 1994;27:2895-902.
|
SPST x STROOP |
7 (3/4)
|
- |
VAMS-Anxiety |
Hetem et al.88. Hetem LA, de Souza CJ, Guimarães ES, Zuardi AW, Graeff FG. Effect of d-fenfluramine on human experimental anxiety. Psychopharmacology (Berl). 1996;127:276-82.
|
D - Fenfluramine |
14 (9/5) |
(18-36) |
VAMS-Anxiety, SBP |
Guimaraes et al.2424. Guimarães FS, Mbaya PS, Deakin JF. Ritanserin facilitates anxiety in a simulated public-speaking paradigm. J Psychopharmacol. 1997;11:225-31.
|
Ritanserin |
15 (4/11) |
(18-34) |
No |
Del Ben et al.2525. Del-Ben CM, Vilela JA, Hetem LA, Guimarães FS, Graeff FG, Zuardi AW. Do panic patients process unconditioned fear vs. conditioned anxiety differently than normal subjects? Psychiatry Res. 2001;104:227-37.
|
Panic patients |
17 (8/9) |
(18-40) |
VAMS-Anxiety |
Monteiro et al.2626. Monteiro-dos-Santos PC, Graeff FG, dos-Santos JE, Ribeiro RP, Guimarães FS, Zuardi AW. Effects of tryptophan depletion on anxiety induced by simulated public speaking. Braz J Med Biol Res. 2000;33:581-7.
|
Tryptophan depletion |
15 (8/7) |
(18-35) |
VAMS-Anxiety |
Shansis et al.2727. Shansis FM, Busnello JV, Quevedo J, Forster L, Young S, Izquierdo I, et al. Behavioural effects of acute tryptophan depletion in healthy male volunteers. J Psychopharmacol. 2000;14:157-63.
|
Tryptophan depletion |
12 (12/0) |
(21-31) |
No |
Silva et al.2828. Silva M, Hetem LA, Guimarães FS, Graeff FG. Opposite effects of nefazodone in two human models of anxiety. Psychopharmacology (Berl). 2001;156:454-60.
|
Nefazodone |
12 (2/10) |
X (SD) = 24.1 (3.7) |
VAMS-Anxiety |
De-Paris et al.77. de-Paris F, Sant'Anna MK, Vianna MR, Barichello T, Busnello JV, Kapczinski F, et al. Effects of gabapentin on anxiety induced by simulated public speaking. J Psychopharmacol. 2003;17:184-8.
|
Gabapentin |
11 (11/0) |
(17-30) |
VAMS-Anxiety, SBP, HR |
Garcia-Leal et al.2929. Garcia-Leal C, Parente AC, Del-Ben CM, Guimarães FS, Moreira AC, Elias LL, et al. Anxiety and salivary cortisol in symptomatic and nonsymptomatic panic patients and healthy volunteers performing simulated public speaking. Psychiatry Res. 2005;133:239-52.
|
Panic patients |
17 (9/8) |
X (SD) = 34.7(12.3) |
VAMS-Anxiety |
Parente et al.3030. Parente AC, Garcia-Leal C, Del-Ben CM, Guimarães FS, Graeff FG. Subjective and neurovegetative changes in healthy volunteers and panic patients performing simulated public speaking. Eur Neuropsychopharmacol. 2005;15:663-71.
|
Panic patients |
16 (9/7) |
X (SD) = 34.5(3.18) |
VAMS-Anxiety, SBP, HR |
Garcia-Leal et al.3131. Garcia-Leal C, Del-Ben CM, Leal FM, Graeff FG, Guimarães FS. Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation. J Psychopharmacol. 2010;24:683-94.
|
Escitalopram |
12 (12/0) |
X (SD) = 24.1(0.89) |
VAMS-Anxiety, SBP, HR |
Bergamacsh et al.3232. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36:1219-26.
|
Cannabidiol - Social anxiety disorder |
12 (6/6) |
X (SD) = 22.9(2.4) |
VAMS-Anxiety, SBP, HR |